Mercer Global Advisors
RLAY icon

Mercer Global Advisors’s Relay Therapeutics RLAY Stock Holding History

Mercer Global Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
16,421
+3,583
+28% +$32.1K ﹤0.01% 2901
2025
Q4 		$109K Sell
12,838
-217
-2% -$1.55K ﹤0.01% 2703
2025
Q3 		$68.1K Buy
+13,055
New +$49.8K ﹤0.01% 2569

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Mercer Global Advisors's RLAY Position: Q1 2026 in Review

Mercer Global Advisors increased its Relay Therapeutics (RLAY) stake by 28% in Q1 2026, buying an estimated $32.1K and bringing the position to 16,421 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #2901.

Mercer Global Advisors first reported a position in RLAY in Q3 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Mercer Global Advisors held 16,421 shares of Relay Therapeutics worth $163K as of Q1 2026.
  • Mercer Global Advisors bought 3,583 Relay Therapeutics shares in Q1 2026, an estimated $32.1K.
  • Relay Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2901 holding.
  • Mercer Global Advisors first reported a position in Relay Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.